Development and validation of the method for determination of related impurities in riboxin tablets

Authors

  • M. V. Rosada National University of Pharmacy, Ukraine
  • N. Yu. Bevz National University of Pharmacy, Ukraine
  • V. A. Georgiyants National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/ophcj.15.863

Keywords:

standardization, Riboxin, tablets, related impurities, HPLC

Abstract

Riboxin (inosine) is used in medicine for treating cardiovascular diseases, so the number of dosage forms containing this substance as an active ingredient is constantly increasing at the Ukrainian pharmaceutical market. When developing quality control methods for a dosage form containing one active substance it is advisable to carry out tests on the presence of related impurities besides identification and assay tests. The article presents the data concerning development of the method for determination of related impurities (hypoxanthine, guanosine) in riboxine tablets using HPLC. The analysis was carried out using a HPLC column (125×4 mm i.d., 5 μm particles) filled with “Lichrospher 60 RP select B”sorbent. The mobile phase adjusted with the phosphate buffer to pH 3.5 was used. The UV detection was performed at 250 nm. The validation characteristics have been studied using the acceptance criteria for the tolerances of the content not more than 0.5% for each impurity, and they confirm specificity (the absence of the effect of excipients), linearity, precision (convergence), accuracy (Δz = 0.79≤max Δz = 5.0, δ = 0.21≤max δ = 0.26, a = 0.48, r = 0.99997>0.9976 for hypoxanthine, and Δz = 0.83≤max Δz = 5.0, δ = 0.17≤max δ = 0.28, a = 0.21, r = 0.99997>0.9976 for guanosine), and the application range for the method proposed.

Downloads

Download data is not yet available.

References

  1. Shlomit Dachir, Dalia Shabashov, Victoria Trembovler, Alexander G. Alexandrovich, Larry I. Benowitz, Esther Shohami. Inosine improves functional recovery after experimental traumatic brain injury. Brain Research, 2014, No.1555, pp.78-88.
  2. Laila Zai, Christina Ferrari, Carlie Dice, Sathish Subbaiah, Leif A. Havton, Giovanni Coppola, Daniel Geschwind, Nina Irwin, Eric Huebner, Stephen M. Strittmatter, Larry I. Benowitz. Inosine Augments the Effects of a Nogo Receptor Blocker and of Environmental Enrichment to Restore Skilled Forelimb Use after Stroke. Journal of Neuroscience, 2011, No.31, pp.5977-5988.
  3. Пат. РФ 1755583 (1994). Заявл.: 31.10.1990. Опубл. 30.08.1994 [Электронный ресурс] Режим доступа http://patents.su/0-1755583-sposobpolucheniya-inozina.html.
  4. Drug master file (for Inosine). “Starlake Bioscieence Co.”, China, 2007, p.68.
  5. Китайська фармакопея. Т. 2. People’s Medical Publishing House, 2005, pp.438-440.
  6. Государственная фармакопея Российской Федерации Ч. 1. Научный центр экспертизы средств медицинского применения. РИБОКСИН (ФС 42-0275-07), 2007, с.624-627.
  7. Александров А. В. Вызовы и возможности документа ICH Q10 «Фармацевтическая система качества». Промышленное обозрение, 2008, №4(9), с.19-21.
  8. FDA / Guidance for Industry-ANDAs: Impurities in Drug Products. Rockville, MD, 2010, p.7.
  9. Jiben Roy. Pharmaceutical Impurities – A Mini-Review. AAPS Pharm. Sci. Tech., 2002, Vol. 3(2), p.7.
  10. Гризодуб А. И. Стандартные процедуры валидации методик контроля качества лекарственных средств. Фармаком, 2006, №1/2, с.3-44.
  11. Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». 1-е вид. Х.: РІРЕГ, 2001, 556 с.
  12. Настанова «Лікарські засоби. Фармацевтична розробка» (Настанова 42-3.1:2004). К.: МОРИОН, 2004, 15 с.
  13. Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». 1-е вид. Доп. 1. Х.: РІРЕГ, 2004, 494 с.
  14. Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». 1-е вид. Доп. 2. Х.: РІРЕГ, 2008, 617 с.
  15. Стандартизованная процедура валидации методик контроля содержания примесей в готовых лекарственных средствах методом жидкостной хроматографии / А. И. Гризодуб, Д. А. Леонтьев, Т. Н. Доценко, В. А. Загорий. Фармаком, 2005, №2-3, с.78-94.

Downloads

Published

2015-12-27

How to Cite

(1)
Rosada, M. V.; Bevz, N. Y.; Georgiyants, V. A. Development and Validation of the Method for Determination of Related Impurities in Riboxin Tablets. J. Org. Pharm. Chem. 2015, 13, 62-67.

Issue

Vol. 13 No. 4(52) (2015)

Section

Original Researches

License

Copyright (c) 2015 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).